231 related articles for article (PubMed ID: 20357824)
1. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
[TBL] [Abstract][Full Text] [Related]
2. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
3. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
Santanam U; Zanesi N; Efanov A; Costinean S; Palamarchuk A; Hagan JP; Volinia S; Alder H; Rassenti L; Kipps T; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12210-5. PubMed ID: 20566844
[TBL] [Abstract][Full Text] [Related]
5. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
[TBL] [Abstract][Full Text] [Related]
6. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
7. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
[TBL] [Abstract][Full Text] [Related]
9. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
Palamarchuk A; Yan PS; Zanesi N; Wang L; Rodrigues B; Murphy M; Balatti V; Bottoni A; Nazaryan N; Alder H; Rassenti L; Kipps TJ; Freitas M; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2555-60. PubMed ID: 22308499
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
[TBL] [Abstract][Full Text] [Related]
11. CD74 is dispensable for development of chronic lymphocytic leukemia in
Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
[TBL] [Abstract][Full Text] [Related]
12. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
[TBL] [Abstract][Full Text] [Related]
13. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
[TBL] [Abstract][Full Text] [Related]
14. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
15. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler C; Piñón JD; Denk U; Heyder C; Hofbauer S; Greil R; Egle A
Blood; 2009 Mar; 113(12):2791-4. PubMed ID: 19168795
[TBL] [Abstract][Full Text] [Related]
16. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
17. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
[TBL] [Abstract][Full Text] [Related]
18. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.
Gagro A; Dasić G; Sabioncello A; Rabatić S; Reckzeh B; Havemann K; Kardum I; Jacksić B; Vitale B
Leuk Lymphoma; 1997 Apr; 25(3-4):301-11. PubMed ID: 9168440
[TBL] [Abstract][Full Text] [Related]
20. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]